Experimental t cell therapy aims to shield vulnerable patients from COVID-19

NCT ID NCT05141058

First seen Nov 01, 2025 · Last updated Apr 21, 2026 · Updated 21 times

Summary

This early-stage study is testing whether specially prepared T cells from donors can help prevent COVID-19 infection in immunocompromised patients who recently received a stem cell transplant. The trial will enroll 24 children and adults to test three different dose levels for safety. Researchers will monitor patients closely for side effects and check whether the therapy boosts their immune response against the virus.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARS-COV-2 INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Children's National Hospital

    RECRUITING

    Washington D.C., District of Columbia, 20010, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University

    RECRUITING

    Baltimore, Maryland, 21287, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.